JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) but reduced the price target from $25 to $22.

November 30, 2023 | 7:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan maintains an Overweight rating on Vera Therapeutics but lowers the price target from $25 to $22.
The reduction in price target by a major analyst like JP Morgan could lead to a negative short term sentiment among investors, potentially causing a decrease in the stock price. However, the maintenance of an Overweight rating suggests a positive outlook on the company's fundamentals, which might mitigate the negative impact to some extent.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100